Effects of zinc supplement on plasma homocysteine level in end-stage renal disease patients: a double-blind randomized clinical trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc and Copper (Supplement) in this randomized controlled trial publication.

The aim of this study was to evaluate effect of zinc (Zn) supplement on serum hCys level in ESRD patients.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

One hundred ESRD patients with Zn deficiency were enrolled in this double-blind randomized clinical trial.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

Fasting plasma hCys and Zn levels were measured before and at 43rd days after the start of the study.

What Was Measured

Topics PubMed links to this paper include Dietary Supplements, Homocysteine, Kidney Failure, Chronic and Zinc.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement).

The publication is from 2013 (Biological trace element research), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Copper (Supplement) compound page, all human trials.